Acumen Pharmaceuticals, Inc. Investment Income, Interest
Acumen Pharmaceuticals, Inc. (ABOS) reported Investment Income, Interest of $1.11 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeInterest · last filed 2026-08-12
- Acumen Pharmaceuticals, Inc. investment income, interest for the quarter ending 2026-06-30 was $1.11M, a 44.86% decline year-over-year.
- Acumen Pharmaceuticals, Inc. investment income, interest for the quarter ending 2026-03-31 was $1.06M, a 56.94% decline year-over-year.
- Acumen Pharmaceuticals, Inc. investment income, interest for the quarter ending 2025-12-31 was $1.32M, a 55.82% decline year-over-year.
- Acumen Pharmaceuticals, Inc. investment income, interest for the quarter ending 2025-09-30 was $1.64M, a 53.22% decline year-over-year.
- Acumen Pharmaceuticals, Inc. investment income, interest for fiscal 2025 was $7.45M, a 47.98% decline from fiscal 2024.
- Acumen Pharmaceuticals, Inc. investment income, interest for fiscal 2024 was $14.32M, a 32.68% increase from fiscal 2023.
- Acumen Pharmaceuticals, Inc. investment income, interest for fiscal 2023 was $10.79M.
| Period end | Investment Income, Interest 3 month | Investment Income, Interest 6 month | Investment Income, Interest 9 month | Investment Income, Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.11M 10-Q · filed 2026-08-12 | $2.17M 10-Q · filed 2026-08-12 | $3.50M derived: sum of 3 quarters · filed 2026-08-12 | $5.14M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $1.06M 10-Q · filed 2026-05-12 | $2.39M derived: sum of 2 quarters · filed 2026-05-12 | $4.03M derived: sum of 3 quarters · filed 2026-05-12 | $6.04M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $1.32M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $2.96M derived: sum of 2 quarters · filed 2026-03-26 | $4.98M derived: sum of 3 quarters · filed 2026-08-12 | $7.45M 10-K · filed 2026-03-26 |
| 2025-09-30 | $1.64M 10-Q · filed 2025-11-12 | $3.65M derived: sum of 2 quarters · filed 2026-08-12 | $6.13M 10-Q · filed 2025-11-12 | $9.12M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $2.02M 10-Q · filed 2026-08-12 | $4.49M 10-Q · filed 2026-08-12 | $7.48M derived: sum of 3 quarters · filed 2026-08-12 | $10.98M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $2.47M 10-Q · filed 2026-05-12 | $5.46M derived: sum of 2 quarters · filed 2026-05-12 | $8.97M derived: sum of 3 quarters · filed 2026-05-12 | $12.78M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $2.99M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $6.50M derived: sum of 2 quarters · filed 2026-03-26 | $10.31M derived: sum of 3 quarters · filed 2026-03-26 | $14.32M 10-K · filed 2026-03-26 |
| 2024-09-30 | $3.50M 10-Q · filed 2025-11-12 | $7.32M derived: sum of 2 quarters · filed 2025-11-12 | $11.32M 10-Q · filed 2025-11-12 | $15.28M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $3.82M 10-Q · filed 2025-08-12 | $7.82M 10-Q · filed 2025-08-12 | $11.77M derived: sum of 3 quarters · filed 2025-08-12 | $14.90M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $4.00M 10-Q · filed 2025-05-13 | $7.96M derived: sum of 2 quarters · filed 2025-05-13 | $11.08M derived: sum of 3 quarters · filed 2025-05-13 | $12.96M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $3.95M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $7.08M derived: sum of 2 quarters · filed 2025-03-27 | $8.96M derived: sum of 3 quarters · filed 2025-03-27 | $10.79M 10-K · filed 2025-03-27 |
| 2023-09-30 | $3.12M 10-Q · filed 2024-11-12 | $5.01M derived: sum of 2 quarters · filed 2024-11-12 | $6.84M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $1.88M 10-Q · filed 2024-08-13 | $3.72M 10-Q · filed 2024-08-13 | ||
| 2021-09-30 | $37.00K 10-Q · filed 2021-11-15 | $41.00K derived: sum of 2 quarters · filed 2021-11-15 | $45.00K 10-Q · filed 2021-11-15 | |
| 2021-06-30 | $4.00K 10-Q · filed 2021-08-16 | $8.00K 10-Q · filed 2021-08-16 | ||
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $1.00K 10-Q · filed 2021-11-15 | ||
| 2020-06-30 | $1.00K 10-Q · filed 2021-08-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |